Additional studies nevertheless have to prove how useful pERK is as a marker for tamoxifen resistance in pre-menopausal breast cancer as well as identifying alternative and potentially more stable markers for activation of ERK that can be useful in clinical routine analyses. This evidence concerns the gene EIF2AK3 and breast cancer.